Is liraglutide available in Australia?

Yes, registered on the ARTG for type 2 diabetes. Weight management indications are prescription-based and require clinical evaluation.

How does liraglutide differ from semaglutide?

Liraglutide is once-daily injectable; semaglutide is once-weekly. Head-to-head trials suggest semaglutide may have slightly greater weight loss.

Verified Peptide ReviewLast reviewed: 19 April 2026

Compound Profile · Metabolic

Liraglutide

Name: Liraglutide Review
Item: Liraglutide
Rating: 4.2
Author: Peptide Reviews Editorial Team

Liraglutide is an injectable GLP-1 receptor agonist approved in several jurisdictions for type 2 diabetes and chronic weight management.

LegalApproved (AU)EvidenceEstablishedHuman useApproved

Compare options View research-grade options Check safety Read full review

7.6/ 10

Peptide Score

Evidence

8.8

Safety

8.4

Regulatory

8.4

Transparency

8.4

Quick verdict

Established daily-dose GLP-1 with longest real-world safety record in class. Smaller weight loss than newer agonists, but durable and well-characterized.

Reality check

What this isn't

Daily injection required (vs. weekly alternatives)
Gastrointestinal side effects common (nausea, diarrhoea) especially early
Smaller mean weight loss than semaglutide or tirzepatide
Requires prescription; not over-the-counter
Thyroid C-cell tumour signal in animal studies — boxed warning
Longest real-world track record in GLP-1 class
Educational research review only — not medical advice

Results snapshot

~5–7%

Mean weight loss (56 weeks)

Weeks

3,700

Participants

Approved

Trial phase

What this means: SCALE program demonstrated modest but durable weight loss. Effective across overweight and obese populations. Not the largest effect size in class, but consistent and long-established.

Reported timeline

What participants experienced

1
Week 0–4
Dose titration protocol; GI adjustment period
2
Week 8–16
Appetite signal emergence; early weight reduction
3
Week 16–28
Progressive weight loss; metabolic marker improvement
4
Week 28–56
Weight loss plateau; sustained metabolic benefit
5
Year 1+
Real-world data supports durability; long-term cardiovascular outcomes established (LEADER trial)

01
Week 0–4
Dose titration protocol; GI adjustment period
02
Week 8–16
Appetite signal emergence; early weight reduction
03
Week 16–28
Progressive weight loss; metabolic marker improvement
04
Week 28–56
Weight loss plateau; sustained metabolic benefit
05
Year 1+
Real-world data supports durability; long-term cardiovascular outcomes established (LEADER trial)

Deep dive

Full Liraglutide review

A GLP-1 receptor agonist administered once daily by subcutaneous injection.

Used clinically for type 2 diabetes and, in some markets, for chronic weight management.

Alternatives

Looking at alternatives?

Compounds with comparable research interest but different evidence, regulatory status, or risk profile.

Metabolic

Semaglutide

Why consider it: Weekly dosing, larger weight loss effect. Approved in AU. More modern than liraglutide with comparable long-term safety data.

View profile

Metabolic

Tirzepatide

Evidence

4.6/ 5

LegalApproved (AU)

Why consider it: Dual GIP/GLP-1 mechanism. Approved in AU. Currently strongest weight loss effect among approved medicines in head-to-head trials.

View profile

Metabolic

Retatrutide

Why consider it: Investigational triple agonist. Largest reported weight loss in trials, but not yet approved. Phase III ongoing.

View profile